Annika Auranen

Medicine & Life Sciences

1. Adenocarcinoma 20%
2. Apolipoproteins 30%
3. Apolipoproteins E 27%
4. Biomarkers 16%
5. Breast Neoplasms 18%
6. Cell Line 15%
7. Cohort Studies 20%
8. Committee Membership 9%
9. Databases 15%
10. DNA Mismatch Repair 30%
11. Endometrial Neoplasms 15%
12. Endometrioid Carcinoma 22%
13. Finland 40%
14. Gene Expression Profiling 26%
15. Genes 13%
16. Genome-Wide Association Study 29%
17. Genomics 6%
18. Glaucoma 24%
19. Guidelines 16%
20. Hematopoietic Stem Cells 25%
21. Hereditary Nonpolyposis Colorectal Neoplasms 33%
22. Heterozygote 31%
23. Homologous Recombination 37%
24. Hysterectomy 50%
25. Incidence 10%
26. Intraocular Pressure 25%
27. Maintenance 17%
28. MEDLINE 5%
29. Multivariate Analysis 18%
30. Neoplasms 38%
31. niraparib 47%
32. Ovarian Epithelial Carcinoma 59%
33. Ovarian Neoplasms 100%
34. Ovary 5%
35. Phenotype 11%
36. Placebos 8%
37. Platelet-Derived Growth Factor beta Receptor 8%
38. Platinum 6%
39. Politics 7%
40. Population 8%
41. Postoperative Complications 22%
42. Progression-Free Survival 29%
43. Proteins 9%
44. Quality of Life 5%
45. Salpingo-oophorectomy 33%
46. Siblings 5%
47. Survival 16%
48. Tertiary Care Centers 22%
49. Therapeutics 8%
50. Workflow 14%